Acrux has been on my radar for a while. The sharp drop in SP is due to the FDA warning with testosterone, but it does not mean that Acrux patents with skin admission delivery, which could potentially be applied with a range of products. For log term investors, I suggest have a closer look at the company's diverse product lines. By the way, there is never 100% true in meidcal world. Testosterone could be harmful but the chance could be extremely small, just as with any other drugs in the market.
ACR Price at posting:
76.0¢ Sentiment: None Disclosure: Not Held
